Ashkenazi Jews are significantly more susceptible than other people to a potentially life-threatening blood disorder if they use the drug Clozapine to treat schizophrenia, according to a new study. The specific set of genes thought to be associated with the disorder is found in 10 percent to 12 percent of the Jewish population in Israel and the United States, but in less than 1 percent of the total white population of the United States, the study says.
JTA has documented Jewish history in real-time for over a century. Keep our journalism strong by joining us in supporting independent, award-winning reporting.
The Archive of the Jewish Telegraphic Agency includes articles published from 1923 to 2008. Archive stories reflect the journalistic standards and practices of the time they were published.
